In this phase II trial, the investigators overarching goal is to demonstrate the feasibility and potential benefit of darbepoetin (Darbe) plus slow-release intravenous (IV) iron to decrease transfusions, maintain iron sufficiency and improve the neurodevelopmental outcomes of preterm infants. Investigators hypothesize that in infants \< 32 completed weeks of gestation, combined treatment with Darbe plus Ferumoxytol (FMX) or Darbe plus low molecular weight iron dextran (LMW-ID) will: 1) be safe, 2) decrease or eliminate transfusions, 3) maintain iron sufficiency, 4) result in higher hematocrit and 5) improve neurodevelopment. Investigators further hypothesize that when compared to oral iron supplementation (standard care), IV iron will be better tolerated, with less effect on the gastrointestinal (GI) microbiome
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Plasma Ferritin at 35-36 weeks PMA
Timeframe: birth to 36 weeks postmenstrual age
Number of IV iron doses required to maintain a ferritin level of > 75 ng/mL
Timeframe: Birth to 36 weeks postmenstrual age (or prior to discharge if this occurs prior to 36 weeks)
Number of Blood transfusions
Timeframe: Birth to 36 weeks postmenstrual age (or prior to discharge if this occurs prior to 36 weeks)
Volume of blood transfusions
Timeframe: Birth to 36 weeks postmenstrual age (or prior to discharge if this occurs prior to 36 weeks)